Back to results
US 7,723,048 B2Granted
Methods of predicting therapeutic response in atopic dermatitis to IL-31 antagonists
AssigneeZymoGenetics, Inc.
InventorsJanine Bilsborough, Jane A. Gross
Life of this patent
Estimating the term…
Abstract
The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
Claims4
A method of predicting the therapeutic response to an IL-31 antibody in an individual with atopic dermatitis comprising the steps of:
- a. obtaining a blood sample from the individual;
- b. obtaining a blood sample from a control;
- c. isolating circulating cutaneous lymphocyte positive T cells from the samples;
- d. activating the isolated cells with 0.5 ug/ml of anti-CD3 antibody;
- e. detecting IL-31 production from the isolated cutaneous lymphocyte positive T cells;
- and
- f. correlating a greater amount of IL-31 production in the individual versus the control with a therapeutic response to the IL-31 antibody.
4 more elements
Dependencies are inferred from the claim text.